IVVD - Earnings call transcript Q2 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Second Quarter Invivyd Earnings Conference Call. [Operator Instructions] As a reminder, this call may be recorded. I would now like to turn the call over to Katie Falzone, Vice President, Corporate Controller. Please go ahead.

Katie Falzone

Thank you, operator. A short while ago, we issued a press release announcing our Q2 2024 financial results and recent business highlights. Press the be are section Board. will found Invivyd of under Committee and today's used of Executive be release and the of website can Events Directors Elia, webcast in the Invivyd's led press by slides respectively. Today's the Chairperson being that in the Presentations Marc That section, and of discussion Board Releases of the Chairperson Investors and Officer; Dr. is Bill Financial He by Duke, Chief Tim Officer; Commercial joined Lee, Chief Robert Officer; Scientific Allen, Chief Dr. and Mark Vice Affairs. of Development Clinical Wingertzahn, President Senior and Medical

statements Reform Securities date from concerning, the today's other These duty change strategy, speak These facts. statements. will are During call, Private activities, plans, assumptions may various to that as prospects of we forward-looking results be are that Litigation discussion, statements differ and forward-looking other uncertainties assumes Invivyd update guidance, actual research our making our within and and this commercial are to Act forward-looking and not financial the statements and and the meaning such implied of regulatory future today. certain among and historical our corporate pipeline only expressed or covered to development time risks, things, over our our of statements subject no cause those materially and

our Marc. filings Additional our it over Form information recent on our U.S. now can with turn made on also Commission, most in the is risk found the including factors and that will business could affect to XX-Q, be Invivyd's website. I available Securities which Exchange

Marc Elia

us. you morning. all Thank Good joining for

our find website. the in X Turning to Slide can you on deck

leadership transition The second quarter XXXX of at Invivyd. with began

risk aims. This broaden to our including advancement. visible major executive the to we expanding morning, was quarter transition populations We second initiatives, ambition summary, and our remains business scope at results operational from for vulnerable to are medical we're some deliver improve broader respiratory our Our viruses, substantial not the COVID-XX. pipeline ability several in immediately of corporate efficiency strategic our our with especially goal our expand posture began way and our a scope rapidly of improve of and value for pleased and and to to yet sharing By footprint commercial update.

While our we are not for virus respiratory our deliver against as season. net into moment are satisfied we growth seeing second major results, acceleration commercial saw eager across and consistent and leaning early quarter, fall/winter XQ, early revenue come the in with are we the -- forward and we we XXXX, to

months, consider available. is care people Americans September, next in immunocompromised vaccine aim likely to We certain and of starting millions are HCPs, remind to teams that boost their the COVID-XX Over together for with disease. more

in were of clinical CANOPY potentially may as emerging such vaccination AstraZeneca risks experience Supernova COVID-XX are trial we those and COVID-XX a studies by been motion the for the our and relevant combined with conducted first VYDXXXX, advancing we all, by are specifically. Further, to by molecule see pipeline be infection. competitor fast from immunologic prophylaxis posed antibody we expand protection from immunocompromised study prophylaxis medicine. humans on stakeholders persons are antibody been field prophylaxis After antibody data this with of the prior PEMGARDA profile that presented could emerging hopeful field studies which this having our Improved but have slow X or our For contemporary broad and as molecules, with these to medicine. in establishment, pleased urgency the frustrated utmost that evolve working medical studies PEMGARDA, who access have the educate to option

all CANOPY additional sharing of to forward look you will data We with soon.

X. Turning Slide to

presentation as available aware unless that this ongoing corporate preview HCPs endemic of such to and updated corporate the today showing clear evolving burden Invivyd of our from images by wave will thought posture, are on are soon. indeed a medical overall the As critical Americans the immunocompromised. be magnitude is not quickly of we Many presented to community or an a these leadership peaking, burden Americans to matter. aims facts of provide COVID-XX on especially the the one

every Moving capable like to or if magically multisystem It will by respiratory get system. of never long-term that clear not other must go key and Slide that inflicting on. a via SARS-CoV-X, transmitted fact head should now all, It to face virus is X. be damage to most, while diseases almost mild, we away organ aerosols

efficacy quickly showed risk compared on season. vaccine VE, ACIP, dismal XX% out over past doing nothing, X. immunocompromised can boost of only broke of relatively have indeed specifically XXth no Slide boosting? the first this might year. is benefit line latest a FDA by as Committee in The to that on boost of or or March estimate Immunocompromised to CDC more than The X year, XXXX from to to more presented after vaccine you Practices, protection of see, reduction performance which, the with Moving months VE X a turn people of as a a persons, XX times Immunization on June Why XXXX-'XX top that recommendation and estimated days. their or every to add hospitalization wish we may to vaccine waned the Advisory the defense data as

even when Americans. blunted should the emergency had to endemic SARS-CoV-X, While for we level PEMGARDA our vaccines experience have authorization was world, no immune as granted may against no in has surprise It emergency people population many the save more. virus millions that experience an do be by immune prior of FDA lives use

the today of a X. can possible is infection exists over experience. Invivyd, try for options that Officer. prior now learned or world confer the even the to booster antibody COVID-XX know Slide valuable exists Most antibodies In use see our make turn that pandemic case today. Tim add Invivyd when titers. us from new We Commercial through Lee, people the both medicines to protection our protective well. I'll COVID alive we during Invivyd to the keep short, treatment immune by to in and antibodies but call about vaccination to Moving context, disease that more category to related Chief uptake an are can comes that well in limited protective protection

Timothy Lee

you, Thank Marc.

Turning a who lives. because that serve with to need Slide to need technology an #XX. could I platform people in immunocompromised, joined Invivyd impact authorized saw of extraordinary for millions the in potential pharmaceutical I those in newly this June of year medical are

onboard my opportunities While situation and team, commercialization a that in across therapies. My to experience bear therapies success own was experts are the Amylyx want network organizations people was I where as different biopharmaceutical brought communities, critically than much unmet laid to at executive for to to is were the second high with from There leadership markedly infused than the most patient biologic substantial Invivyd where career the start commercial coming led Biohaven prior for quickly that dynamics and who and in medical groundwork several at moved key experienced Invivyd. working PEMGARDA. The a the today highlight. it I've vaccine perceive years commercializing quarter. such need, fighting Alexion, of own which has been me found with rather by recently, we of

clinical EUA, have immediately which been and in at time community, near work on the we zero of was awareness accelerating. a First, there began the of PEMGARDA

has the COVID-XX ourselves perception been a Second, be This providers, given we is is among a healthcare many in that find addressed seasonal wave it summer to underway. the in, there that is fall. threat ironic substantial currently

as into March there EUA of April, course, ambient late the United Third, the at quickly. quite was has COVID-XX usual, changed in States, which, low

what Their the privilege habits frame. to need and of activation that providers and to an respiratory work from Their observe not real, without own. their imminently community. of motivation who the about of outcomes is an winter just time We're from in robust fall hearing care disease opportunity I've and directly lives appear adverse interest to Now members real. to the the our their that immunocompromised more begin bring protection a focused immunocompromised lifestyles. protection the changed take in aim I very preparing live additional of community. Since advantage has the had joined, relatively campaign health risk matches normal intensity on They're major of the fear is passionate in we reclaiming we to is

that Turning certain metrics commercial to for we'll on Slide reporting a clarity launch go-forward basis be We've XX. refined usefulness. and

You into acceleration and will marked across quarter. see these a both in quarter numbers the second the third coming

by of target $X our we as covered full is provides and population with you the PEMGARDA As Medicaid, Medicare reimbursement copay. which know, and XX% reported,

of regional commercial While we're the the aware we're a These total payers largest majority cover covered, position calculate commercial not of successful from reimbursement to collectively and yet commercial payers. in national lives. lives

our acceleration. expect continue to We this efforts

are quarter by of immunocompromised people, risks the fall part, early Turning second work the to transplant for Invivyd attuned that well to by mandate consider to that and in perception in pose we Slide some And related Survey who to keenly as and populations and XX. healthcare hematologists group protection regard COVID-XX. their to the saw aware providers the the large oncologists. yet winter. and seasonal This surgeons specifically

with substantially actively population. to this evolve pervasive, be impact weeks months disease healthcare patient that will thinking and their the We the can these over providers persistent on engaging coming

over for X recommended age years Turning June, the fall. universal every to of CDC Slide this XX. In boosting American COVID-XX

pharmacies weeks. in if millions And like of vaccination week resembles vaccines We XXXX, process. will expect 'XX within Americans the begin updated anything per

considering boosting earlier data patients. alluded strongly suggest on is certain a but additional vaccine his strategy, protective remarks, protection for effectiveness Marc the immunocompromised As in critical

these to of dynamics. look take will We advantage

Slide to XX. Turning

serve of the We risk is COVID-XX. who to stated revenue protection have additional net communities. and severely high for represents an conversion those to need. these are building a of people in And at opportunity are guidance team immunocompromised infrastructure The to a percentage severe all of previously who offer small moderately our to a

XX. Turning to Slide

healthcare commercial commercial Over few weeks, second next traditional will established and population immunocompromised Invivyd the with begin awareness. awareness quarter, the messaging drive domains over groundwork the in to digital and provider the

opportunity generate the balance hearing critical forward of upcoming evaluating look to every XXXX. carefully are single and work. We feedback in these to on your awareness through We'll our markets

Wingertzahn, We about the pipeline. my colleague, Mark? to subtle. With I'd be turn that, are our aiming not to like over call Mark talk to to

Mark Wingertzahn

Thank you, Tim.

Turning XX. to Slide

effort including to know, VYDXXXX biophysical you on the affinity via As in improve the in against of potency properties, pemivibart. viruses an maturation vitro the XBB identified measured pemivibart lineage of we've

that may and patient more for system variable and doses of efficacy potency protection COVID-XX in measured you are sVNA the achieve can to antibody directly meaningful realize, are all if required may variables an drives for of in development than that antibody. that translate friendly These lower lower the turn doses approaches. As are administration allow routes titer, improvements for all levels other pharmacodynamic ICXXs equal, a of to intravenous

Slide to Turning XX.

[ felt that with are for have first-in-human of VYDXXXX We for titers dosing could to for provide end COVID-XX both achieved interrogate of interrogating planned strongly be with This plans intramuscular to achieving study antibody a depending ] subcutaneous pleased the and multiple to We approval Australian optionality if dosing. and one intravenous, titers prevention suitable upon study from and August. at FX administration flexibility that routes could authorized. treatment begin

be to ECXX pharmacokinetic ultimately our of viruses, administration by in testing potency regulatory by Slide early human demonstrated will Turning profile and by and vitro doses dialogue VYDXXXX against XX. course, measured with agencies. and across observed the vivo relevant profile the routes, and safety The half-life product in VYDXXXX relevant the determined

I'd our infused ongoing like you evolution envision we the our of in perhaps a progress can virology intravenous updating an Chief tighter Officer, any followed on fall. With to call by Allen, altogether. our intravenous to therapy dose However, of elimination to delivery lower including Scientific that, field. move discuss through the loading permutations, maintenance to We the field as from Robbie Robbie? over look a forward turn dose to we to emerging number of the

Robert Allen

Thank Mark. you,

to Slide Turning XX.

update quickly the SVNA with Given the a describes possible our view of we performance view we provide some titers then steps. on in surrogate visit topics, molecules next clinical these and investor of thought the marker interest an of that we would how

differences assay point form the PEMGARDA that to from pseudovirus tenfold key virus immunobridging while which range you X.XX including antibody FDA's recall estimates between marked that of FDA in thinking COVID on variability, on fold authentic variability, from depending range addressed the a intrinsic the This directly is can not consideration wide assays contemplated been potential values directly First, of is see adintrevimab and in assays. in concept on have several the use an up of of bioequivalence potency differences fact with by analysis form to has bridging sheet, PEMGARDA the where analytics the a assays X.XX. and neutralization analysis. a immunobridging, with antibodies These

analyses this yield from in course, a type limited to X although, moving point quickly these estimated XX. ECXX saltation of the calculation. a before of seen Single potency from therefore, became useful associated Omicron an complete Turning assays. and that evolution conception more viral was to overall systems of conception analytics estimates Slide complex in antibody we underlying a great variant assay of lineages virus and the that We, SVNA ongoing in that indexes more obsoleted to single course, intrudes the become sweeping evolution all analysis can, average virus by sort. reflects of for titer Even interested a since might to Omicron, This shifting values there soup, rapidly of these disparity ECXX have as opposed portrait by propensity weighted event. activity, into are

XX. have regulatory In Turning COVID-XX, this see in data average evaluate public our weighted of monoclonal pseudoviral average potency of you over authorization to ECXXs actions relocation de-authorization. associated analysis of to serial weighted time and example, its that to Slide furtherance approach depicted Evusheld In antibody against can and observed and authorization. analyzed reflected we

Turning to actions antibodies past authorization authorization, and this we of across of extended provide treatment further authorized and insight Slide To both to prevention. historic for revocation XX. analysis regulatory

When to the compelling emergence pemivibart analysis Turning [ a portrait and Slide we extend XX. ]. to VYDXXXX,

by substantial of could assay of meaningful of by define have and becoming inherent meaningful have change values of to challenged the structural these selection average virus this day. This the lineages dozens appreciable emerged, a the of outcompeted. change. the variability This been systems clinically fluctuate since lack be continues data. time predicted then Pemivibart weighted epitope, that evolution without the Over biology conserved but VYDXXX,

VYDXXXX difficult see signs attention lack up of has Invivyd the early improved due meaningful this potency to of potential and of our its on platform has our it its is Turning stable pipeline, chart keep with values. to evolution. built change, significant virus and to improvement although to potency improved inevitability with demonstrated ICXX

in of there of conservation aim to to take are principles advantage general order we of resistance of increase evolution. antibodies the epitopes However, the our to virus around effects the

such an in our of perfect. speed. this as We insights be to platform attractive design, innovate and will biological never discovery The that by And these endeavor. at power our we hope aid accompany data structural will the

Turning to Slide XX.

pseudovirus The in analysis is handle asset United questionable in for matter to high-quality half viral value the in turn reassess time occur the number. pemivibart among potency and preliminary determine a challenge of of to discovered these services accurate relates of in several the of virus been neutralization partners, exploratory JN.X the FDA potential it virus our is such us. also study, and generated receipt a authentic has perform in pemivibart of of against laboratory authentic potency virus value the against with rendered rapidly JN.X for analyses independently which also which applied of the FDA contamination CANOPY very Another steps, and of happened commercial and in activity in timely generally titers generated event value, has virology a viruses dialogue BSL-X SVNA of preliminary winter informative XXXX. of on similar evolving that an in their about or the our Invivyd is a versus academic matter authentic Reassuringly, to meaning stocks, JN.X this ability States reliability. clinical SARS-CoV-X virus the to the The Recently, estimated dominance can data. for virus second during provider one reliable, appropriate Invivyd partners JN.X will commercial authentic setting weeks. And reliable to have on a JN.X other Potentially in next a labs series JN.X. this secure

presentation. Overall, finalized prepared and virology As look and accuracy forward improve soon usefulness, our when we a key informativeness Mark all the stakeholders. as to sharing these company data goal is for of data noted, to to

also limitations bioassays to these treat the by making must and clear interest those and in of of be are the protect that medicines they diseases. While us of importance, business have clear cellular acknowledged vulnerable

for over for this been CFO, see Duke, remarks FDA many acumen Bill especially to opportunities the and years when we and to collective constant are We final Q&A. now the contemporary for topic, to improve our with like and in dialogue see prior all from, have on data can turn call example, CANOPY clinical to our Supernova. I'd

William Duke

Robbie. Thanks,

exciting Moving history. is to our Slide now in XX. Invivyd an at Right moment

the are forward guidance looking provided and are pleased activities expansion and our of reaffirm to to commercial revenue cash previously. We rapid

As will refine in be remain guidance. we But a we the through comfortable with boundaries fall, position move the it. that now, we to within for

we contracted doses we that our are greater Invivyd operations next this afford the the efficiency see. biopharmaceutical COGS been which exhausting majority intend significant burn to work. may benefits we of model clinical company, addition, product PEMGARDA, streamlining a is rate molecule, have we starting produce associated quantities approximately In Of last integrated expenses After see of the with of profile to transition depending rapidly VYDXXXX. At and of upon over point, fully includes our to compared the our although note, XXX,XXX and PEMGARDA. have supply, quarter production to of that lower VYDXXXX, to

product strengthen operator the to equity sources questions. Our are multiple however, to virus we dilutive upcoming forward over to raising source the now a fall/winter balance respiratory money. non-dilutive Nonetheless, sales the sheet operating commercial favorite open we the in season. I'll and push to with and looking benefit with associated call Mainly, are turn discussions capital for we potential remains should contribution. capital our of incremental in of assess

Katie Falzone

you can please Operator, questions? open Operator? for

Marc Elia

questions queue. us the give there know moment, are you'll if we all in Well, a

repairing is on work we'll going whatever So wrong.

going you this try a Apparently we're Well, results the ourselves question? not. are be Okay. point this us with Evan on Wang, the should to for and doing at line fascinating.

Boran Wang

Can you hear me? Hello?

Marc Elia

Now, we can hear you.

Okay.

Boran Wang

Yes. me? would you're for Can great. X to me. you first hear, Tim, you more Great perspective or just off, then guess, I guess, in months success can share some of I see Tim, still did what's guess little immunization make But been optimize some your of, of can there's you and what of season? And putting in, what hear we're all love you in. X the existing, progress.. guess, Okay, I work describe you fall you did I X what's needed -- guess, bit on, just goal now I you're the of some guess to guess, I and I a of wave and the on ahead early commentary some shared you've of can terms kind there? in of, commercial how like kind seeing changes the what on acceleration what terms remaining seeing of what's in to think results I XQ, summer this

Timothy Lee

Happy Thank Yes. you. to.

over I how different just around biologic, that think starting as comments which commercialize made was I the one the months, look infused world. we're an than we is last the X of towards to rapidly back vaccine

right deep I bit on One team -- of through looking things excited and doing we a immediate helping can is things an here. We go loose little away. we're and a the market those them let brought on what we're do lens, seasoned look at at to really to

to that infusion had pull simple work digital was latest not PEMGARDA We As much We've updating just already, are work sites like with at through. the continue to our happened. doing there rapidly work available. increase corporate things look and that it, locator beginning started we that digital looked campaign

that said over seeing now we're coming we rapidly country XXX think are over and there I who right this what before, more around on the think are I is sites -- going. work a With board. of that be infrastructure has focused and and those. there's where what towards to applied we're that, we've And on, is been that effort level build it's

the people as question if to talk start out articles but about Internet it's your single I published wave, -- figured it's think but my summer that talk to that the every that Internet on the is because more summer history, now, population. to I didn't it's interesting general you about, noticing open as have I'm wave probably the we that don't the people, increased this know around I something it's want algorithms effect time something having

into immunocompromised, are and lean group really we people who is for where are think who I protection. needing that of really looking

the starting that been had patient the not do was to we're starting listen to think I we're to done and thing and to that other speak with that community. previously, engage

that are I urgency immunocompromised we and so think think key And better there's act as glean I be that -- can better said how us for many partners. can allowing Marc I order population the the this is from and to people learnings alluded to with we that, think focused honestly, the also on granted. do little bit here. to be many group things motivational more quite true the And for in a needs what us I take opportunity these stories

So sure I said, hopefully, missed I'm I touched happy clarify. but kind of scribbled all Evan, I'm your you as down someone, I them to points. probably

Boran Wang

to some of some you Is of expect weighted in this then about how stocking And here? what thinking Whether you would to kind do expected weighted? to be relative of expect the -- half the be of there guess, do any to XQ degree I sales second vaccines? the like COVID more some be it We're these vaccines. potential

Marc Elia

exchanging community, then frankly, disproportionately a fundamental is such some the begins. ways somewhere not back-to-school early XQ, sensitive from acceleration. medical and think Northern outdoors fairly and and different, stated this preference habits. there summer, geared we've this There but in feel the Tim non-threatening don't results on are first over to think can substantial observably happens. The of reason can had the And in that noted me and in all I look, fascinating I magical wave. And alluded the progression on particularly on dimensions ways second harmonics look, which, in a work. big period curve. of and was speak together, all to comment to those people The season, changing whatnot. COVID of at the are respond up we've it big push think, rise game right, on our notably of back reinvigorated and then of to these was want COVID-XX is the the multiple I a taken growth Tim quiet the not summer something we dynamic we're and go an reality that school. that people course, mainly front the point at own we've this Hemisphere, time work we case, part the own let others inventory and to. But all of which in weeks sets we revenue So comfortable achieved of habits and, it's quarter, overall That's broad a air right in ambient are is couple When The gratifying, the re-led of advantage in in the game. our but us, starting in as seemingly

would facets the it many broad temperatures as the medical prevention. and in their toward seem the Northeast, back indoors attention go great, though drop of they As turn a great complex

year, And so in for Easter probably like first selling Christmas a somebody a little candy. more it's retailer or us, bit this a

hit Your the So whole but look spring, come the business work out, to XQ over position was happen September, in of to us that hard. put doesn't into right? meaningfully purpose probably

look October we time appreciate And November quickly, distribution, for the about think big think this at vaccine and over our do, September, our the you when as position this not think, well. Tim, in distribution I a be period, inventory? of we're is But as to prophylaxis that we're when that and because first know are we So launching. year, very, months. us will is that expectation I they will you very

Timothy Lee

-- you stocking. think I see you'll see Yes, won't

to to we're channel. for shipping will with continue those our them. sure want that ensure as need what to and needed have in provide that the and We we to increased think basis they do continuing is inventory have in inventory availability I make just-in-time

Operator

next Maxwell from Instructions] [Operator question Stanley. will come Skor Morgan Our from

Maxwell Skor

to second availability? availability, about positive question, to the reflect me, larger let's you generally to second infusion assume you reasonable Is does it And get the directionally, locator for what then opportunity of into, recommendation.? Two the And are centers? this basically. a say, EUA hear efforts regarding academic the were you'll And year-end? by Great. magnitude if making site just get

Marc Elia

Great. Okay.

with So on timing it discussion has purview certainly as and FDA, but submitted our EUA, to not the topics treatment variety will are been of not indeed of to the we choose they within that opine you a anything do. do or noted, it's on have on in might

we've timing, would the think I together. out though let's always But sort felt hypothesizing sort all reasonable. be of find of your as

that In I is reach domains reach terms of will will of rate people American of than look, at the higher commonly for magnitude opportunity, prevention. it that think clear they in treatment medicine, multiple for a

it. I of think in the be so -- always case COVID, that's not the best play, but

put hands with XXXX, and our the treatment, But for But down position like quite yet So view, think, course, next that full are in to pemivibart I for future around potentially both you. additive. numbers rolling out really feel the we molecule a PrEP, in though very potentially we'll we have of see. as therefore, not to we're quite with and

that? you Mark, So add anything would on

Mark Wingertzahn

think I you. was said, well that Thank No, Marc.

Marc Elia

Okay.

So locator? then

Timothy Lee

around the the infusion locator. Thank question you for

I updated I'll think what time you in tell now. being is real right

So major centers. if you infuse for the on currently So It the are us. a today, medical an academic around we you infusing multiple able were and priority is paths, country do starting at the of right? that all to is of representation it's What it mentioned accurate PEMGARDA. act are not to sites look to

in community. well last needs to we that private with dedicated can and an population patient it. In how with educate for sites that, have opportunity this as there access the field is on for to a better we've going every X infusion PEMGARDA team begun create who We ensure day out partner there talks doing some single months for that immunocompromised parallel that out

numbers really we'll as in And and remarkably as I tracks, something days the infusion parallel so national you speeds. running as we're major infusion online in multiple trains positive is at the happen and locator centers well centers that go centers But see on to as increase different academic but continue monitor, if think well. X we next they local

Operator

from [Operator will come question Instructions] from And next Jefferies. Yee Michael our

Unknown Analyst

This in any ] for please EU Kyle status. OUS? is ] [ [ Michael. give Could updates of question sort real filing A on quick us you on the

Marc Elia

Yes, sure.

but in we So something to is that think here think more Invivyd, not quickly, germane discussion to face under is light us. I on PEMGARDA. if OUS over would XXXX constant very of time, I topic this don't migrated constraints a supply surprise at the it

we're always it's willing the exploring field. the sort to geography, are conception of think on limit a support not de So regulators for to there profile is offered of with that and entirely to the what drug harmonized And particularly a opening do by we therefore, something a of I those new are novo their things, pemivibart. global probably

global the well, right to you horizon that one of So with so and that display regulatory wish there's COVID I now, statement think I during constructively publicly engaged. highlighting. constructively course, on certainly would, think global bears and that a find But nothing there may problem, us the us is engage is, Olympics. are agencies on

Unknown Analyst

quick a And me. follow-up you. Got for

on briefly ordering QX? So talk visibility could already through halfway about given you please your we're

Marc Elia

Sure.

real clarify, big you oh, -- note the as some quarter. acceleration that with it public where major, I is we to the we prophylaxis. further think prepared along note willing in to our COVID almost, is Day, So commercial we our expect see health commercially weeks updated into availability game towards a endeavor know, from I there, Labor X will of vaccines, social until and I were in think, remarks is the drive I think, don't still somewhere But to results

we meaning. The as what something results that step a have lot most view whole And don't to we So ahead. meaning change, step the that we going have of change observed but of a longer is the isn't be most wait. news to is lie good in

Operator

speakers' phone no am And questions from [Operator Instructions] our showing lines. further I

Marc Elia

this look all the fielding morning, Thank day. you thank Well, we us much you. very Great. questions and for through your to forward later joining

Operator

Thank This you. for today's Thank conclude does participation. program. your you

have Everyone, day. You a wonderful may now disconnect.

Invivyd (IVVD) 14 Aug 242024 Q2 Earnings call transcript